Spruce Biosciences, Inc., a pharmaceutical company, received a notification on October 24, 2024, from the Nasdaq Stock Market indicating that the company has not met the minimum bid price requirement for continued listing. The company's common stock is at risk of being delisted if it does not regain compliance.
The Nasdaq Listing Qualifications Department granted Spruce Biosciences an additional 180 days, until April 21, 2025, to meet the minimum closing bid price of $1.00 per share. During this period, if the company's stock achieves a closing bid price of at least $1.00 for ten consecutive business days, Nasdaq will confirm that the company has complied with the listing rule.
As a result of the notice, Spruce Biosciences' stock will transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective today. This change does not immediately affect the stock's listing status.
The company is considering various strategies to address the bid price deficiency, including potentially executing a reverse stock split. However, there is no guarantee that these measures will be successful in maintaining compliance with Nasdaq's requirements.
If Spruce Biosciences fails to regain compliance by the April 21, 2025 deadline, it may receive a delisting notice from Nasdaq. The company would then have the option to appeal the decision before a Nasdaq Hearings Panel.
InvestingPro Insights
As Spruce Biosciences (SPRB) grapples with its Nasdaq listing challenges, InvestingPro data provides additional context to the company's financial situation. The company's market capitalization stands at a modest $23.96 million, reflecting its current struggles. Despite the recent notification from Nasdaq, SPRB has shown a strong return of 28.56% over the last month, indicating some positive momentum.
InvestingPro Tips highlight that SPRB holds more cash than debt on its balance sheet, which could provide some financial flexibility as it navigates this challenging period. However, the company is quickly burning through cash, a concern that aligns with its listing woes. This cash burn rate could potentially impact the company's ability to implement strategies to regain compliance with Nasdaq's minimum bid price requirement.
Investors considering SPRB's situation should note that InvestingPro offers 12 additional tips for this stock, providing a more comprehensive analysis of its financial health and market position. These insights could be valuable for those monitoring the company's efforts to maintain its Nasdaq listing and evaluate its long-term prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.